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1. Introduction  
Cardiovascular disease (CVD) is a leading cause of mortality in developed countries (Jan et 
al., 2010; Yang et al., 2008). Despite a long held understanding and strong characterization of 
the traditional and non-traditional risk factors for CVD, some mechanisms of CVD onset 
have only recently been uncovered. As a chronic inflammatory autoimmune disease, 
atherosclerosis and its progression involve innate and adaptive immune systems. Using new 
concepts and technologies to improve the current understandings of the molecular 
pathogenesis of inflammatory and immune responses would lead to the future development 
of novel therapeutics for these diseases.     
Biomedical literature and databases, available in electronic forms, contain a vast amount of 
knowledge resulting from experimental research (Ishii et al., 2007; Palakal et al., 2007). In the 
past decade, both traditional hypothesis-driven research and discovery-driven “-omics” 
research, including genomics, transcriptomics (Liang et al., 2005), proteinomics, 
metabolomics, glycomics, lipidomics, localizomics, protein-DNA interactomics, protein-
protein interactomics, fluxomics, phenomics (Joyce & Palsson, 2006), and antigen-omics 
(http://www.cancerimmunity.org/links/databases.htm) (Houle et al., 2010; Shimokawa et 
al., 2010; Weinstein, 1998;2002), has generated a tremendous amount of data and established 
many experimental data-based searchable databases. These databases include PubMed, 
nucleotide database, protein database, and other databases generated by the National 
Institutes of Health (NIH)/National Center for Biotechnology Information (NCBI) (see the 
NCBI handbook at http://www.ncbi.nlm.nih.gov/books/NBK21101/) and other 
institutions. This development has not only provided resources, but also raised 
unprecedented challenges and opportunities for biomedical scientists to develop more 
systemic and panoramic approaches to analyze the data contained in the databases and 
generate new hypotheses. The inconsistency between the vast amount of experimental data, 
various searchable databases, and relatively smaller numbers of database-mining research 
papers (< 50 papers on database mining in inflammation and immune responses listed in 
the PubMed) indicate the challenges that experimental biomedical scientists face, which 
include both technical/methodological difficulties and out-of-date concepts. 
Traditionally, medical literature search using the Index Medicus was the major approach for 
biomedical scientists to identify knowledge gaps and preparing new hypotheses. However, 
this approach has been significantly enhanced by more systemic approaches such as 1) 
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NCBI-PubMed search and Google Scholar search; 2) experimentally screening cDNA 
libraries and various arrays (nucleic acid arrays, antibody arrays, protein arrays and 
metabolic arrays) (King et al., 2005; Loza et al., 2007; Pandey et al., 2004; Warner & 
Dieckgraefe, 2002); and 3) mining experimental databases (Chen et al., 2010; Jan et al., 2010; 
Ng et al., 2004; Yang et al., 2006a; Yang et al., 2006b; Yin et al., 2009). The screening analysis 
of microarray data often requires bioinformatic methods, algorithms, and expertise. In 
comparison, database mining offers many advantages. First, database mining requires much 
less bioinformatic assistance in each laboratory when compared to the generation of 
algorithms required in microarray analyses, since the purpose of generating databases is to 
use bioinformatic approaches to mine easily organize the experimental data for biomedical 
scientists to mine (Spasic et al., 2005). Second, database mining enables full-value extraction 
from costly experimental data, and third, it provides panoramic analyses on existing 
knowledge gaps by generating new hypotheses for further experimental research. However, 
database mining requires biomedical scientists to have more conceptual advances than 
technical assistances. The purpose of database mining is to analyze experimental data 
deposited by various research projects, rather than predicting theoretic results based on 
pure theoretical bioinformatic studies. Thus, database mining is not limited to sequence 
comparisons of nucleic acids and proteins (Mount, 2004), sequence alignments, analysis of 
hydrophobicity index and functional domain prediction of proteins. Additionally, database 
mining has not generally been listed as a required course for graduate and postdoctoral 
studies, which presents a challenge of properly training young biomedical scientists with 
essential database mining techniques. On top of these aforementioned challenges, reviewers 
from peer-reviewed database mining publications often mistakenly regard the experimental 
data in electronic forms deposited in databases as “non-experimental or theoretical” and 
demand ridiculous additional verifying experiments to be performed, even requiring the 
use of outdated experimental techniques or methods. To overcome these difficulties, 
bioinformatic scientists will have to work together with biomedical colleagues and delve 
into the biological significance of database mining projects, rather than sticking to an 
argument of “no algorithms means no bioinformatics”. Already, more and more database 
mining papers have been published as scientists put aside their differences. For example, the 
2011 (18th) database issue of the journal “Nucleic Acid Research” features descriptions of 96 
new and 83 updated online databases covering various areas of molecular biology (Galperin 
& Cochrane, 2011). The Nucleic Acids Research online Database Collection, available at: 
http://www.oxfordjournals.org/nar/database/a/, now lists 1330 carefully selected 
molecular biology databases. In addition, 32 databases and analysis resources of 
immunological interest have been established (Salimi et al., 2010). Moreover, our recent 
invited review lists 11 B cell antigen epitope databases and 13 T cell antigen epitope analysis 
resources (Jan et al., 2010). These progresses suggest that a data mining approach has 
gradually been accepted as mainstream practice in analyzing experimental data and 
generating new hypotheses for various projects (Salimi et al., 2010). 
Our lab has successfully pioneered major advances in database mining in the fields of 
adaptive immune reactions, innate immune responses, and inflammation (Chen et al., 2010; 
Jan et al., 2010; Ng et al., 2004; Virtue, 2011; Yang et al., 2006a; Yang et al., 2006b; Yin et al., 
2009). In this chapter, we will summarize the general approaches, principles, and databases 
used and new working models proposed in our database mining research. This discussion 
will prove to be important and useful for most biomedical scientists, since many are not 
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often involved in the bioinformatic algorithm generation, but may want to use database 
mining methods in their research either as parts of existing experimental studies or as free-
standing projects. Of note, the database mining concept is not “brand new”. Medical 
research has a long history in full-value extraction from costly data. For example, a meta-
analysis uses a statistical approach to combine the results of several epidemiological studies 
that address a set of related research hypotheses. This practice started well over 100 years 
ago and has been widely used in various disease-related researches 
(http://en.wikipedia.org/wiki/Meta-analysis) (Egger & Smith, 1997; Egger et al., 1997). We 
believe that the practice of database mining will become a routine exercise to identify 
existing knowledge gaps and to generate new hypotheses. 
2. Principles of database mining 
In recent years, many databases regarding immune responses and inflammation have been 
established (Jan et al., 2010; Yang et al., 2006a), which have expanded the scope and depth of 
a publicly searchable online repertoire of tools. The results derived from the database 
mining analyses have become parts of many research papers or free-standing papers. 
Although projects may vary in format, database mining approaches follow the same set of 
principles (Fig. 1): 1) Hypothesis: A clearly-presented hypothesis based on the current 
biomedical literature search in a given field and previous experimental data in the lab is 
required to carry on a database mining project as we reported (Ng et al., 2004; Yan et al., 
2004), which is similar to that of experimental projects. Of note, the database mining referred 
here focuses on database mining as a free standing project rather than as a part of 
experimental research; 2) Scope: Database mining scopes in terms of gene numbers are far 
more than that examined in experimental approaches. For example, our own research will 
examine mRNA transcript expressions of about 30 genes including all the reported toll-like 
receptors, NOD-like receptors, and inflammatory caspases in more than ten tissues. This 
scope allows us to obtain a panoramic view on the expressions of inflammatory pathways 
without focusing on a single gene in many tissues (Yin et al., 2009); 3) Suitable databases: 
Databases that are suitable for examining the hypothesis are available for online analytic 
search, which is also similar to the methods and reagents for experimental projects; 4) 
Sizable experimentally verified data for generating confidence intervals with statistical 
significance: To consolidate the results generated from database mining, the experimentally 
verified data are published by various laboratories, which can be used to generate 
statistically significant confidence intervals by using the same online analysis tools as we 
reported (Virtue, 2011). In this study, our analysis in the TargetScan yielded 524 
microRNAs, which were predicted to participate in 1368 unique interactions with the 33 
inflammatory gene mRNAs. To ensure relevance, we examined the context value and 
percentage of experimentally verified microRNAs. Confidence intervals were generated 
from 45 interactions between 28 experimentally verified human microRNAs and 36 genes 
found within the Tarbase, an online database of experimentally verified microRNAs 
(http://diana.cslab.ece.ntua.gr/tarbase/) (Papadopoulos et al., 2009; Sethupathy et al., 
2006). These experimental interactions were also selected based on their confirmation by 
luciferase reporter assays and single site specificity. The 45 microRNA-mRNA interactions 
that met these criteria were then evaluated in TargetScan to determine the microRNA 
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Develop a well-presented hypothesis based on experimental data and 
analysis on current knowledge gap
Determine the scope, focus, and pathway for database mining
Find suitable databases that contain experimental data, which are 
organized with appropriate bioinformaticexpertise
Find sizable experimental data for generating confidence intervals, 
which are consolidated with statistical tools of sample size 
determination
Identify verifiable experimental methods
Propose a new working hypothesis/working model for further 
experimental research
 
Fig. 1. Detabase mining flow-chart and principles. 
context values and percentages. Analysis of this data yielded a mean and standard deviation 
(SD) of -0.25 ± 0.12 and 76.07 ± 19.07 for context value and context percentage, respectively. 
The intervals were then constructed and the lower limits (the mean - 2 x standard 
deviations) were calculated for context percentage (76.07-1.96 (19.07/SQRT (46)) = 76.07 - 
5.51 = 70.56) and context value (-0.25-1.96(0.12/SQRT (46) = - 0.25 - 0.04= -0.22). All 
predicted microRNAs interactions with a context value ≤-0.22 and context percentage ≥70 
were accepted. Using the lower limit thresholds for context value and percentage, 297 out of 
the 524 predicted microRNAs met the criteria and were considered equivalent to the 
experimentally verified microRNAs. In order to generate valid confidence intervals, sample 
sizes have to be estimated with statistical tools of sample size determination (Rosner, 2000) 
as we reported (Ng et al., 2004); 5) Verifiable methods: Experimental methods are available 
www.intechopen.com
 
Database Mining: Defining the Pathogenesis of Inflammatory and Immunological Diseases 
 
147 
to verify the data generated by the database mining (Yan et al., 2004); and 6) A new working 
model/hypothesis: Through database mining, a new knowledge gap will be identified, and 
a new hypothesis will be proposed to test fewer, much more-focused genes in further 
experiments. The following sections will illustrate these principles in our own publications 
(Chen et al., 2010; Jan et al., 2010; Ng et al., 2004; Virtue, 2011; Yang et al., 2006a; Yang et al., 
2006b; Yin et al., 2009). 
3. Database mining example 1: Stimulation-responsive alternative splicing is 
an important mechanism in generating self-antigen epitopes (Ng et al., 2004; 
Xiong et al., 2006; Yan et al., 2004; Yang et al., 2006a; Yang, 2007) 
In our invited review, we pointed out that the identification and molecular characterization of 
self-antigens expressed by human malignancies, that are capable of elicitation of anti-tumor 
immune responses in patients, have been an active field in tumor immunology (Yang & Yang, 
2005). More than 2,000 tumor antigens have been identified, and most of these antigens are 
self-antigens (Yang & Yang, 2005). Despite this, the important question of how non-mutated 
self-protein antigens, generated from normal cells and tumor cells, gain immunogenicity and 
trigger immune recognition remained unanswered (Yang & Yang, 2005). Mutations may be 
responsible for some aspects of elevated immunogenicity underlying certain tumor-specific 
antigens (p53 and Ras), while chromosome translocations and abnormalities, such as 
expression of the fusion oncogene Bcr-Abl in chronic myelogenous leukemia (Clark et al., 2001; 
Pinilla-Ibarz et al., 2000; Yotnda et al., 1998; Zorn, 2001) (Yang et al., 2002; Yang et al., 2001) are 
responsible for other aspects. However, the mechanism underlying the immunogenicity of 
most non-mutated self-tumor antigens is their aberrant overexpression in tumors (Yang & 
Yang, 2005). Zinkernagel et al (Zinkernagel & Hengartner, 2001) suggested that the 
overexpression of self-antigens or novel antigenic structure, overcomes the threshold of 
antigen concentration at which an immune response is initiated (Shlomchik et al., 2001). This 
threshold might be lower for certain untolerized regions of certain antigen epitopes. 
Overexpressed genes, often encode tumor antigens up to 100 fold. These genes are identified 
by serological identification of self-antigens by screening a cDNA library with patients’ sera 
(SEREX) (Sahin et al., 1995), which may reflect the inherent methodological bias for the 
detection of abundant transcript (Preuss et al., 2002). The overexpression of tumor antigens in 
tumors may result from transcriptional and post-transcriptional mechanisms. We recently 
demonstrated that overexpression of tumor antigen CML66L in leukemia cells and tumor cells 
via alternative splicing is the mechanism for its immunogenicity in patients with tumors (Yan 
et al., 2004; Yang et al., 2001). This not only illustrates the principle of overexpression of tumor 
antigen, but also elucidated alternative splicing as its molecular mechanism (Yan et al., 2004). 
A significant proportion of the SEREX-defined self-tumor antigens are autoantigens (Chen, 
2004), for example, CML28 that we identified is autoantigen Rrp46p (Yang et al., 2002). Using 
this information gathered from SEREX, we hypothesized that alternative splicing is a general 
mechanism for the overexpression of untolerized self-antigen epitopes in tumors and 
autoimmune diseases. In order to test this hypothesis, we database mined the NIH-NCBI 
AceView database to examine the potential mechanisms of how non-mutated self-proteins 
gain new untolerized structures that trigger immune recognition (Ng et al., 2004). The 
AceView database provides a curated, comprehensive, and non-redundant sequence 
representation of all public mRNA sequences (mRNAs from GenBank or RefSeq, and single 
pass cDNA sequences from dbEST and Trace). These experimental cDNA sequences are first 
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co-aligned on the genome, and then clustered into a minimal number of alternative transcript 
variants and grouped into genes (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/). 
Our results showed that alternative splicing occurs in 100% of autoantigen transcripts. This is 
significantly higher than the approximately 42% rate of alternative splicing observed in the 
9554 randomly selected human gene transcripts (p<0.001). Within the isoform-specific regions 
of the autoantigens, 92% and 88% encoded MHC class I and class II-restricted T-cell antigen 
epitopes, respectively, and 70% encoded antibody binding domains. Alternative splicing can 
be canonical or non-canonical. Canonical splicing removes introns that have 5’GT and 3’AG 
consensus flanking sequences (GT-AG rule) (Lewin, 2000). Our results demonstrated that 80% 
of the autoantigen transcripts undergo non-canonical alternative splicing, which is 
significantly higher than the less than 1% rate in randomly selected gene transcripts (p<0.001). 
These studies suggest that non-canonical alternative splicing may be an important mechanism 
for the generation of untolerized epitopes that may lead to autoimmunity. Furthermore, the 
product of a transcript that does not undergo alternative splicing is unlikely to be a target 
antigen in autoimmunity (Ng et al., 2004). To consolidate this finding, we also examined the 
effect of proinflammatory cytokine tumor necrosis factor-ǂ (TNF-ǂ) on the prototypic 
alternative splicing factor (ASF)/SF2 in the splicing machinery. Our results show that TNF-ǂ 
downregulates ASF/SF2 expression in cultured muscle cells. This result correlates with our 
finding of reduced expression of ASF/SF2 in inflamed muscle cells from patients  
with autoimmune myositis (Xiong et al., 2006). Based on our and others’ data, we  
recently proposed a new model of stimulation-responsive splicing for the selection of 
autoantigens and self-tumor antigens (Yang et al., 2006a) [also see Fig. 1 at 
(http://preview.ncbi.nlm.nih.gov/pubmed/16890493)]. Our new model theorizes that the 
significantly higher rates of alternative splicing of autoantigen and self-tumor antigen 
transcripts that occur in response to stimuli, such as proinflammatory cytokines, could induce 
extra-thymic expression of untolerized antigen epitopes to elicit autoimmune and anti-tumor 
responses. By using B lymphocyte (B cell) antigen epitope analysis databases and T cell 
antigen epitope analysis databases listed in Tables in our recent invited review 
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858284/pdf/JBB2010-459798.pdf) (Jan et 
al., 2010), we showed that protein sequences encoded by alternatively spliced exons are 
sufficient to equip antibody-binding antigen epitopes and major histocompatibility complex 
(MHC) class I- and MHC II-restricted T cell antigen epitopes to stimulate B lymphocytes and T 
lymphocytes, respectively (Ng et al., 2004). Of note, our model not only applies to non-
mutated self-tumor antigens associated tumors and autoantigens associated with various 
autoimmune diseases, but also to the composition and expansion of the self-antigen repertoire 
of stem cells. Our additional database mining study has generated a new model of differential 
epitope processing for MHC class I-restricted viral antigen epitopes and tumor antigen 
epitopes (Yang et al., 2006b). Our reports have demonstrated the principles of database mining 
in adaptive immune responses. 
4. Database mining example 2: Three-tier model for inflammasome/caspase-1 
activation and inflammation privilege of tissues are important mechanisms 
underlying the differences in the readiness of inflammation initiation in 
tissues 
Atherosclerosis is the leading cause of morbidity and mortality in industrialized society. 
Several “traditional” risk factors have been identified for atherosclerosis including 
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hyperlipidemia, oxidized low density lipoprotein, cigarette smoking, diabetes, 
hypertension, obesity (Ross, 1992), and hyperhomocysteinemia (HHcy), etc. Chronic 
vascular inflammation is an essential requirement for the progression of atherosclerosis in 
patients (Hansson, 2005). Recent progress in characterizing pathogen-associated molecular 
patterns’ (PAMPs) receptor families (PAMP-Rs) and inflammasomes (the protein complex 
for activation of caspase-1) has further emphasized the importance of proinflammatory 
cytokine interleukin-1ǃ (IL-1ǃ) signaling in bridging proatherogenic risk factors to initiate 
inflammation (Yang et al., 2008). However, constitutive expression levels and expression 
readiness of PAMP-Rs, inflammasome components and proinflammtory caspases in tissues 
remained poorly defined. We hypothesized that PAMP-Rs, inflammasome components, 
proinflammatory caspases, IL-1, and IL-18 are differentially expressed in cardiovascular 
tissues. To examine this hypothesis, we mined the NCBI-UniGene database, analyzed cDNA 
cloning and DNA sequencing data from tissue cDNA libraries and studied expression 
profiles of Toll-like receptors (TLRs), cytosolic nucleotide binding and oligomerization 
domain (NOD)-like receptors (NLRs), inflammasome components, inflammatory caspases, 
and caspase-1 cleavable inflammatory cytokines. The UniGene database provides an 
organized view of the transcriptome with information on protein similarities, gene 
expression, cDNA clone reagents, and genomic location 
(http://www.ncbi.nlm.nih.gov/unigene), in which each UniGene entry is a set of transcript 
sequences that appear to come from the same transcription locus (gene or expressed 
pseudogene). After analyzing the data from the UniGene database, we made several 
important findings: (1) Among 11 tissues examined, vascular tissues and heart express fewer 
types of TLRs and NLRs than immune system tissues including blood, lymph nodes, 
thymus, and trachea; (2) Brain, lymph nodes, and thymus do not express proinflammatory 
cytokines IL-1ǃ and IL-18 constitutively, suggesting that these two cytokines need to be 
upregulated in response to inflammatory stimuli in the tissues; and (3) based on the 
expression data of three characterized inflammasomes (NALP1, NALP3 and IPAF 
inflammasomes), the examined tissues can be classified into three tiers: the first tier tissues 
including brain, placenta, blood, and thymus express inflammasome(s) in constitutive 
status; the second tier tissues have inflammasome(s) in nearly-ready expression status (with 
the requirement of upregulation of one component); and the third tier tissues like heart and 
bone marrow, require upregulation of at least two components in order to assemble 
functional inflammasomes. Based on the expression readiness of inflammasomes in tissues, 
we propose a new working model of three-tier responsive expression of inflammasomes in 
tissues and suggest a new concept of third tier tissues’ inflammatory privilege, which 
provides an insight on the differences of tissues in initiating acute inflammations. This 
model suggests that (a) first-tier tissues with constitutively expressed inflammasomes 
initiate inflammation quicker than second and third-tier tissues; and (b) second tier tissues 
(requiring one component of upregulation) including vascular tissue, and third tier tissues 
including heart (requiring more than one component upregulation) are in an inducible 
expression status of inflammasomes. The inducible expressions of inflammasomes are 
presumably mediated through various signal pathways that initiate inflammation, and the 
interplay between the signal pathways, may take a longer time and overcome a higher 
threshold than first tier tissues. Traditional concepts of immune privilege suggests a 
protective mechanism from autoimmune destruction based on the lack of expression of 
antigen-presenting self-major compatibility complex (MHC) molecules in tissues (Yang & 
Yang, 2005). The lack of expression of self-MHCs in immune privileged tissues including 
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testis results in the failure of self-antigen presentation that stimulates the hosts’ immune 
system, thereby protecting immune privileged tissues from autoimmune destruction. 
Similarly, we proposed a new concept of tissues’ inflammatory privileges that emphasize a 
protective mechanism against tissue destruction mediated by inflammasome/IL-1ǃ-based 
innate immune responses. In our new concept of tissues’ inflammatory privilege, vascular 
tissue and heart disproportionally express fewer types of TLRs and NLRs and may only 
inducibly express inflammasomes, thus preventing against uncontrolled inflammatory 
destruction mediated by inflammasome-based innate immune responses (Streilein & Stein-
Streilein, 2000). Our new concept and model may also explain the potential differences 
between cardiovascular tissues and other tissues in initiating acute inflammation. The first-
tier tissues may have a higher probability of experiencing acute inflammation than the 
second-tier and third-tier tissues.  
We and others showed that elevated levels of plasma homocysteine (Hcy), termed 
hyperhomocysteinemia (HHcy), is an independent risk factor, equivalent to hyperlipidemia, 
for cardiovascular diseases (CVD) including coronary heart disease and stroke (Maron & 
Loscalzo, 2009; Wang et al., 2003; Zhang et al., 2009). Recently, we performed an additional 
database mining study using to examine the expression of more than 20 homocysteine 
metabolic enzymes and methylation enzymes in >20 tissues in humans and mouse (Chen et 
al., 2010). We generated a new model of how hypomethylation (a post-translational protein 
modification) modulates the expressions of homocysteine-metabolizing enzymes (Chen et 
al., 2010). Taken together, our studies have demonstrated the principles of database mining 
in innate immune reactions.  
5. Database mining example 3: A group of anti-inflammatory microRNAs may 
play critical roles in inhibiting the expression of proatherogenic molecules 
Previous research has established that numerous genes are upregulated in atherogenesis 
through epigenetic or genetic transcriptional mechanisms (Turunen et al., 2009). However, 
transcription-independent mechanisms have received far less scrutiny. Recent publications 
suggest that microRNAs, a newly characterized class of short (18-24 nucleotide long), 
endogenous, non-coding RNAs (Bartel, 2009), contribute to the development of particular 
disease states by regulating diverse biological processes such as cell growth, differentiation, 
proliferation, and apoptosis (Zhang, 2008). This biological control is accomplished by post-
transcriptional gene silencing (Naeem et al., 2010) through Watson and Crick base-pairing 
predominately at the 3’-untranslated region (3’UTR) of messenger RNAs (mRNAs) (Cordes 
et al., 2009; Rasmussen et al., 2010). This pairing can be further characterized as “perfect” or 
“near perfect”, leading to target mRNA cleavage and degradation, or “imperfect”, causing 
the inhibition of mRNA translation (Naeem et al., 2010). With the identification and 
sequencing of more than 800 human microRNAs thus far, it is thought that up to 30% of 
human genes may be regulated by microRNAs (Cheng et al., 2010; Zhang, 2008). Supporting 
evidence suggests that microRNAs function as key players during critical stages of cellular 
development and finely tune gene expression in the maintenance of routine cellular 
functioning (Baek et al., 2008). Furthermore, microRNAs can act on transcription factors, 
which lead to a broad indirect cellular effect as a result of their widespread gene modulating 
nature. In addition, the recent research has demonstrated that changes in microRNAs 
expression patterns are connected to several pathological conditions including 
cardiovascular disease and atherosclerosis. These studies primarily focused on 
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characterizing microRNAs in atherosclerosis disease models, which had been previously 
reported to have elevated expression in disease conditions (Haver et al., 2010; Rink & 
Khanna, 2010). Thus, current microRNAs research has failed to provide a panoramic view of 
how microRNAs regulate proatherogenic inflammatory genes in a panoramic view and 
whether upregulation of proatherogenic inflammatory genes is the result of anti-
inflammatory microRNA downregulation. To address these issues, we hypothesized that a 
group of anti-inflammatory microRNAs may regulate the expressions of proatherogenic 
molecules (Virtue, 2011). We then developed a novel database mining approach using three 
types of databases including the online microRNA target prediction software TargetScan 
(http://www.targetscan.org/) (Dong et al., 2010; Rosero et al., 2010; Vickers & Remaley, 
2010), the Tarbase, an online database of experimentally verified microRNAs 
(http://diana.cslab.ece.ntua.gr/tarbase/) (Papadopoulos et al., 2009; Sethupathy et al., 
2006), and the online microRNA.org expression database (http://www.microrna.org/ 
microrna/home.do) (Betel et al., 2008), in concert with a statistical analysis strategy 
established in our previous database mining publications (Chen et al., 2010; Ng et al., 2004; 
Shen et al., 2010; Yang et al., 2006b; Yin et al., 2009). Our unique research using database 
mining yielded several key findings. First, we discovered that the expression of 33 
inflammatory genes (mRNAs) is upregulated in atherosclerotic lesions and second, that the 
mRNAs of those genes contain structural features in their 3’UTR for potential regulation by 
microRNAs. Furthermore, these structural features are statistically identical to 
experimentally verified 3’UTR microRNAs binding sites. Third, 21 out of the 33 
inflammatory genes (64%) are targeted by highly expressed microRNAs while the 
remaining 12 inflammatory genes (36%) are targeted by normally expressed microRNAs. 
Fourth, it was also established that 10 of the 21 highly expressed microRNA-targeted 
inflammatory genes (48%) were targeted by a single microRNA, suggesting the specificity of 
microRNA regulation. Meanwhile, 12 out of the 25 highly expressed microRNAs (48%) 
targeted single inflammatory genes while the other 13 microRNAs targeted multiple 
inflammatory genes. Finally, it was determined that the microRNAs targeting 
atherosclerotic inflammatory genes use statistically higher numbers of “poorly conserved” 
binding interactions than the control group of microRNAs from the confidence interval. 
These results suggest that the microRNAs regulating atherosclerotic inflammatory genes 
possess special features (Virtue, 2011). 
Previous research has shown that microRNAs participate in modulating atherosclerosis-
related processes including hyperlipidemia (microRNA-33, microRNA-125a-5p), 
hypertension (microRNA-155), plaque rupture (microRNA-222, microRNA-210), and 
atherosclerosis itself (microRNA-21, microRNA-126) (Rink & Khanna, 2010). However, 
whether certain microRNAs play a role in preventing the disease development remains 
unknown. One of the most interesting findings from our study is that the 25 microRNAs 
that are highly expressed under normal untreated conditions target 21 out of the 33 (64%) 
atherosclerosis-upregulated inflammatory genes. The important result suggests a novel 
mechanism where a group of highly expressed anti-inflammatory microRNAs suppress the 
upregulation of proatherogenic inflammatory genes under normal physiological conditions. 
It has been well established that microRNAs play important roles in fine-tuning 
developmental processes and participate in the development of diseases such as cancer. Our 
results are the first to suggest that microRNAs may play a protective role by suppressing 
proatherogenic genes to maintain healthy arteries. Our conclusion is supported by other 
publications, which show that 7 out of the 20 microRNAs identified in this study were 
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downregulated in the experimental studies by various proatherogenic factors (Chen et al., 
2009; Elia et al., 2009; Ji et al., 2007). Together, our studies have demonstrated the principles 
of database mining in inflammation.    
6. Conclusion 
Active research in human and mouse genomes, transcriptomes, microRNAs transcriptomes, 
proteomes, and antigen-omes in the past decade has generated a tremendous amount of 
data and established many experimental data-based searchable databases. This provides 
unprecedented opportunities for biomedical scientists to develop more systemic and 
panoramic approaches to analyze the databases and generate new hypotheses. In this 
chapter, we briefly summarize our pioneering efforts in using our new database mining 
methods to address important questions in inflammatory and immunological diseases. The 
new principles and basic methodologies of database mining developed in our laboratories 
are elucidated in the following studies: 1) stimulation-responsive alternative splicing model 
for the generation of untolerized autoantigen epitopes; 2) a three-tier model for 
inflammasome/caspase-1 activation and inflammatory privileges of tissues; and 3) a group 
of anti-inflammatory microRNAs in inhibiting proatherogenic gene expression during 
atherogenesis. With recent technological breakthroughs, database mining has provided 
significant new insights and hypotheses in specifying the novel directions for experimental 
research. 
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